Skip to content
Screener

Absci Corporation ABSI Accounts Receivable

Accounts Receivable at other companies

Schrodinger logo
SchrodingerSDGR
$21.39M+112%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$38.42M-45.1%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$25.75M+44.0%
Assembly Biosciences logo
Assembly BiosciencesASMB
$451K
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$254.48M+231%
Xencor logo
XencorXNCR
$42.23M-11.2%

Other financials

Income statement

See full
Revenue$215.0K-81.8%
Operating income-$30.8M-11.2%
Net income-$29.6M-12.3%
EPS (diluted)-$0.19+9.5%

Balance sheet

See full
Cash & equivalents$9.7M-84.9%
Total debt$4.0M-37.2%
Total equity$172.0M-13.5%
Total assets$195.6M-15.9%

Cash flow

See full
Operating cash flow-$26.3M-20.5%
CapEx$30.0K+20.0%
Free cash flow-$26.3M-20.5%

Valuation

See full
Market cap$1.41B+235%
Enterprise value$1.4B+279%
P/S765.8×+664×

Profitability

See full
Operating margin-6,723%-14,525pp
Net margin-6,450.8%-13,699pp
FCF margin-5,365.2%-9,300pp

Returns & leverage

See full
Return on equity-63.9%+28.0pp
Debt / equity0.0×
Current ratio6.6×+0.9×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerAssetNet.

The source filing: Absci Corporation’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:24 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001672688-26-000088

Contract assets are generated when contractual billing schedules differ from revenue recognition timing and the Company records a contract asset when it has an unconditional right to consideration. As of March 31, 2026 contract assets were $0.1 million. Contract liabilities are recorded as deferred revenue when cash payments are received or due in advance of the satisfaction of performance obligations. As of March 31, 2026 and December 31, 2025, contract liabilities were $1.0 million and $1.2 million, respectively. During the three months ended March 31, 2026, the Company recognized $0.2 million as revenue that had been included in deferred revenue at the beginning of the period. During the three months ended March 31, 2025, the Company recognized $0.4 million, as revenue that had been included in deferred revenue at the beginning of the period. The Company expects the remaining contract liabilities to be recognized as revenue between one to two years.

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Absci Corporation's accounts receivable?
Absci Corporation (ABSI) reported accounts receivable of $100K in Q1 2026.
How has Absci Corporation's accounts receivable changed year-over-year?
Absci Corporation's accounts receivable decreased by 92.8% year-over-year, from $1.38M to $100K.
What is the long-term trend for Absci Corporation's accounts receivable?
Over 5 years (2020 to 2025), Absci Corporation's accounts receivable has grown at a 58.5% compound annual growth rate (CAGR), from $100K to -$1M.
What does accounts receivable mean?
Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.

Ask your AI about Absci Corporation's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude